Immunomedics→Gilead Sciences
Acquisition · Cash · announced Sep 13, 2020
Announced
Sep 13, 2020
Closed
Oct 22, 2020
Economics
Cash()
Pre-deal · pre-deal mark: 2020, year precision · rounding grid ±$100M · Gilead Sciences 8-K filing, SEC EDGAR — Immunomedics acquisition (NASDAQ:IMMU)
$88/share, ~$21B
Target
Immunomedics
Breast Health · Clinical / therapeutic
HQ Morris Plains, NJ · Founded 1982
Developer of Trodelvy (sacituzumab govitecan), first-in-class Trop-2 ADC for metastatic triple-negative breast cancer (mTNBC)
- Business Wire — Gilead/Immunomedics announcement (Sep 13, 2020)
- Gilead Sciences press release (Sep 13, 2020)
- SEC EDGAR — Immunomedics merger filing
Acquirer
Gilead Sciences
Healthcare
HQ Foster City, CA
Biopharmaceutical company expanding into oncology — Trodelvy ADC for triple-negative breast cancer via Immunomedics acquisition
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Trodelvy (sacituzumab govitecan) is first-in-class Trop-2 ADC approved for metastatic triple-negative breast cancer — transforms Gilead's oncology portfolio; >$10B risk-adjusted revenue potential by 2030
Evidence ladder
Secondary (press / IR)
Business Wire — Gilead/Immunomedics announcement (Sep 13, 2020)
Secondary (press / IR)
Gilead Sciences press release
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_8k.htm
Open source
Limitations
- $88/share, ~$21B
- Pre-deal valuation sourced from: Gilead Sciences 8-K filing, SEC EDGAR — Immunomedics acquisition (NASDAQ:IMMU). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Biotheranostics | Hologic | Jan 5, 2021 | ||
| Focal Therapeutics | Hologic | Sep 26, 2018 | ||
| Faxitron Bioptics | Hologic | Jul 31, 2018 | ||
| SuperSonic Imagine | Hologic | Jun 21, 2019 |
Patient empowerment context
Empowerment context — Immunomedics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Presented with clinical trial as treatment option (Press release)1 in 5cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Press release)54%cited HLTH 2022Mapping source →
- Oncologist listens; wishes reflected in treatment plan (Press release)56%cited HLTH 2022Mapping source →
- Not aware of survivorship resources (Press release)2 in 3cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Flatiron Health
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.